Evidence map›Paper›PMID 40351424›Full record

ArticleFrontiers in pharmacology2025

Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights.

Guanbin Huang, Tongtong Xia, Dongxiao Yang, Muwen Lin, Yiping Luo, Yuchan Li, Hualin Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guanbin HuangDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Tongtong XiaDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Dongxiao YangDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Muwen LinDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yiping LuoDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yuchan LiDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Hualin ChenDepartment of Lung Cancer, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), represents a significant oncological challenge due to its aggressive behavior, high metastatic potential and poor prognosis. HER2 mutation is a rare but critical oncogenic driver associated with resistance to traditional therapies among NSCLC subtypes, including chemotherapy and tyrosine kinase inhibitors (TKIs). Trastuzumab deruxtecan (T-DXd), a next-generation antibody-drug conjugate, combines HER2-targeted therapy with a potent cytotoxic payload, enabling specific tumor cell eradication and addressing intratumoral heterogeneity through its bystander effect. This case report details the treatment of a 69-year-old male with advanced

Indexed as

antibody-drug conjugatecentral nervous system metastasesfirst line treatmentHER2-mutant NSCLCtrastuzumab deruxtecan

Identifiers

PMID40351424
PMCPMC12061705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.